Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Microarray analysis of a multiple myeloma cell line, MM1S, treated with adenosine A2A and Beta-2 Adrenergic Receptor agonists in combination with dexamethasone

ABSTRACT: We have used an agnostic approach to identify drug combinations by using combination high throughput screening (cHTS) technology and make the surprising discovery that adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic, selective and novel agents that enhance glucocorticoid activity in B-cell malignancies. We used the microarray study to understand the synergistic mechanism between dexamethasone and A2A receptor agonist or Beta-2 Adrenergic receptor agonist in a multiple myeloma cell line, MM1S. MM1S cells were treated with CGS-21680 or Salmeterol alone, or in combination with dexamethasone for six hours for RNA extraction and hybridization on Affymetrix microarrays.

ORGANISM(S): Homo sapiens

SUBMITTER: Winnie Tam

PROVIDER: E-GEOD-30644 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

Microarray analysis of a multiple myeloma cell line, MM1S, treated with adenosine A2A and Beta-2 Adrenergic Receptor agonists in combination with dexamethasone

Project description:We have used an agnostic approach to identify drug combinations by using combination high throughput screening (cHTS) technology and make the surprising discovery that adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic, selective and novel agents that enhance glucocorticoid activity in B-cell malignancies. We used the microarray study to understand the synergistic mechanism between dexamethasone and A2A receptor agonist or Beta-2 Adrenergic receptor agonist in a multiple myeloma cell line, MM1S.

2012-04-01 | GSE30644 | GEO

Gene expression profile of MM1S under normoxic and hypoxic conditions

Project description:MM1S cells have been cultured under normoxic and hypoxic conditions, and gene expression profiling has been performed using the Affymetrix Human Genome U133 Plus 2.0 array.

2014-08-01 | GSE52315 | GEO

Expression data from Mus musculus white adipose tissue

Project description:We used microarrays to detail the gene expression profile during WAT -beige transition by treatment of beta adrenergic receptor agonist . Stromal vascular fractions (SVF) from mice (n = 3/group) that received vehicle or beta3 adrenergic receptor agonist, CL, treatment were served for RNA extraction and hybridization on Affymetrix microarrays. We are trying to find out angiogenic factors genes dynamics during white adipose tissues (WAT) - beige transition.

2014-03-15 | E-GEOD-55934 | biostudies-arrayexpress

Clenbuterol exerts antidiabetic activity through metabolic reprogramming of skeletal muscle cells

Project description:Activation of the sympathetic nervous system causes pronounced metabolic changes that are mediated by multiple adrenergic receptor subtypes. Systemic treatment with β2-adrenergic receptor agonists results in multiple beneficial metabolic effects, including improved glucose homeostasis. To elucidate the underlying cellular and molecular mechanisms, we chronically treated wild-type mice and several newly developed mutant mouse strains with clenbuterol, a selective β2-adrenergic receptor agonist. Clenbuterol administration caused pronounced improvements in glucose homeostasis and prevented the metabolic deficits in mouse models of β-cell dysfunction and insulin resistance. Studies with skeletal muscle-specific mutant mice demonstrated that these metabolic improvements required activation of skeletal muscle β2-adrenergic receptors and the stimulatory G protein, Gs. Unbiased transcriptomic and metabolomic analyses showed that chronic β2-adrenergic receptor stimulation caused metabolic reprogramming of skeletal muscle characterized by enhanced glucose utilization. These findings strongly suggest that agents targeting skeletal muscle metabolism by modulating β2-adrenergic receptor-dependent signaling pathways may prove beneficial as antidiabetic drugs.

2022-08-26 | MTBLS467 | MetaboLights

H3K4me3 ChIP in multiple myeloma MM1S cells in the presence and absence of KDM5-C70

Project description:In this experiment we demonstrate the use of an inhibitor of the KDM5 family of histone demethylases, KDM5-C70, on H3K4me3 marks in the multiple myeloma cell line MM1S. KDM5-C70 increases H3K4me3 in a global fashion across the genome. Examination of H3K4me3 mark across MM1S cells treated with either KDM5-C70 or vehicle control

2016-04-05 | E-GEOD-78206 | biostudies-arrayexpress

Gene expression profile of MM1S under normoxic and hypoxic conditions

Project description:MM1S cells have been cultured under normoxic and hypoxic conditions, and gene expression profiling has been performed using the Affymetrix Human Genome U133 Plus 2.0 array. We used microarrays to dissect the possible changes occurring at the mRNA level in normoxic cells versus hypoxic cells.

2014-08-01 | E-GEOD-52315 | biostudies-arrayexpress

Effect of norepinephrine and UK 14,304 treatment on murine small intestinal organoids

Project description:Murine small intestinal organoids were stimulated with the general α and β adrenergic receptor agonist norepinephrine and the complete potent and specific α2 adrenergic agonist UK 14,304 (both 1uM) or vehicle controls for 4 days. Afterwards, they were harvested for RNA isolation and proliferation and differentiation gene expression patterns were assessed.

2023-05-09 | GSE230088 | GEO

β2 adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses

Project description:RNA sequencing of ILC2s sorted from β2 adrenergic receptor agonist-treated and non-treated mice

2018-11-27 | GSE108884 | GEO

Gene expression changes induced by BRD9876 in MM1S cells

Project description:The goal of this study was to identify transcriptional changes induced by a novel compound BRD9876 as a starting point to identify the compound's mechanism of action. Compound-treated cells are compared in duplicate with cells treated vehicle control (DMSO).

2014-12-16 | E-GEOD-64178 | biostudies-arrayexpress

H3K4me3 ChIP in multiple myeloma MM1S cells in the presence and absence of KDM5-C70

2016-04-05 | GSE78206 | GEO